Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $108.3552W HIGH $182.99
Volume
1.86 M
Value Traded
259.62 M
Short % Float
1.79%
Days to Cover
2.4
-2.26%Week
+0.41%1 Month
+23.03%3 Month
+53.32%6 Month
-13.35%5 Year
+275%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
48.49 B
EPS (TTM)
5.11
P/E Ratio
33.67
Ent. Value
50.68 B
Total Shares
281.93 M
Float Shares
281.04 M
Insiders
0.32%
Institutions
95.61%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
A Catalyst Timeline
Dated clinical, regulatory and corporate events for Agilent Technologies, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Agilent Technologies, Inc.
3Total events
0Upcoming
1Tier-1 (high impact)
2026 to 2026Coverage
Event history 3
▲EU ApprovalEx-US Regulatory
EU certification of PD-L1 IHC 22C3 pharmDx (Code SK006) as companion diagnostic for epithelial ovarian, fallopian tube, or primary peritoneal carcinoma
epithelial ovarian, fallopian tube, or primary peritoneal carcinomasource ↗
▲Product LaunchPost-Market
Launch of AI-driven analysis module for Agilent xCELLigence RTCA eSight
Past FDA Catalysts and PDUFA Decisions
How A actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Agilent Technologies, Inc. is a diagnostics company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every A program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Dolsten MikaelDirector | Sell | -634 4,923.68 held | $151.38 | 09/04/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in A
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PARKMAN HEALTHCARE PARTNERS LLC | 1.3 % | 13.61 M | 100.00 K |
Ownership Trends
A Short Interest
Shares sold short, counted twice a month.
1.79%
Short % of Float
of tradable shares sold short
5.0M
Shares Sold Short
-4.1% vs prior count
2.4 Moderate
Days to Cover
trading days of normal volume to buy every short share back
2.1M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How A ranks across every disease it competes in
Competitive Position is a premium feature
See how A ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialA News
AAgilent to Announce Fourth-Quarter Fiscal Year 2026 Financial Results on Nov. 23
Agilent Technologies Inc. will announce its fourth-quarter financial results for fiscal year 2026 on November 23, after market close. A conference call will take place at 1:30 p.m. PST to discuss the results. Investors can access the call via Agilent's Investor Relations website.
Read more →AAgilent to Acquire Proscia, Advancing AI-Enabled Digital Pathology and Scientific Intelligence
Agilent Technologies has announced its acquisition of Proscia, a digital pathology software provider, for $240 million, with potential additional payments based on performance. This acquisition is expected to enhance Agilent's position in the rapidly growing digital pathology market and strengthen its offerings in precision medicine. Proscia's platform will integrate with Agilent's existing solutions, aiming to improve workflows in laboratories and biopharma settings.
Read more →AAgilent Introduces the NovoStation Sample Preparation System for Automated Flow Cytometry Workflows
Agilent Technologies has launched the NovoStation Sample Preparation System, an automated platform aimed at enhancing flow cytometry workflows. This system significantly reduces manual preparation time, achieving over 90% efficiency while maintaining data quality. It integrates seamlessly with Agilent's flow cytometers, allowing for a streamlined sample-to-answer process. The NovoStation will be unveiled at the ICCS 2026 conference.
Read more →AAgilent Introduces Gen5 AI Cell Identification Module for BioTek Automated Cell Imagers
Agilent Technologies has launched the Gen5 AI cell identification module, enhancing its BioTek automated imaging systems. This new software add-on utilizes AI for cell identification and segmentation, streamlining the imaging analysis process. It eliminates the need for traditional threshold settings, making it easier for users to analyze cell images.
Read more →AAgilent Launches TapeStationDx Systems for Clinical NGS Sample Quality Control
Agilent Technologies has launched the Agilent 4150 and 4200 TapeStationDx systems, along with TapeStationDx software, aimed at improving quality control for DNA and RNA samples in clinical next-generation sequencing. These systems are CE-IVD labeled, ensuring they meet regulatory standards for clinical use. This expansion enhances Agilent's automated electrophoresis portfolio.
Read more →ACORRECTING and REPLACING Agilent Announces Cash Dividend of 25.5 Cents per Share
Agilent Technologies Inc. has announced a cash dividend of 25.5 cents per share, which will be paid on October 28, 2026. This announcement corrects a previous error regarding the payment date and record date for shareholders. The dividend reflects Agilent's commitment to returning value to its shareholders.
Read more →AAgilent Announces Cash Dividend of 25.5 Cents per Share
Agilent Technologies Inc. has declared a quarterly dividend of 25.5 cents per share, set to be paid on October 6, 2026. Shareholders on record as of October 28, 2026, will receive this dividend. Future dividends will depend on the approval of Agilent's board of directors, reflecting the company's ongoing commitment to shareholder returns.
Read more →AAgilent to Participate in J.P. Morgan U.S. All Stars Conference
Agilent Technologies Inc. announced its participation in the J.P. Morgan U.S. All Stars Conference. CEO Padraig McDonnell and CFO Adam Elinoff will engage in a fireside chat scheduled for September 23, 2026, in London. The event will be accessible via a live audio webcast on Agilent's Investor Relations website.
Read more →AAgilent Announces Retirement of Board Chair Koh Boon Hwee, Appointment of Glenn Boehnlein to Board of Directors
Agilent Technologies announced the retirement of Koh Boon Hwee as board chair, effective September 4, 2026, after more than 20 years of service. Koh has been a director since 2003 and served as independent chair since 2017. The company also appointed Glenn Boehnlein to the board, signaling a strategic shift in leadership.
Read more →AAgilent Expands Digital Pathology Offering with U.S. Launch of the Agilent S540MD Slide Scanner System
Agilent Technologies has launched the Agilent S540MD Slide Scanner System in the U.S. after receiving FDA clearance. This new whole slide imaging digital scanner aims to enhance diagnostic efficiency in pathology laboratories, responding to the growing demand for high-throughput solutions in clinical settings.
Read more →AAgilent Reports Third-Quarter Fiscal Year 2026 Financial Results
Agilent Technologies Inc. reported strong financial results for the third quarter of fiscal year 2026, with revenues reaching $1.88 billion, marking an 8.1% increase from the same period last year. The company also saw a rise in GAAP net income to $362 million, translating to earnings of $1.28 per share. This performance reflects positive growth trends for Agilent.
Read more →AAgilent Research Catalyst Award Presented to Eastern Institute of Technology, Ningbo
Agilent Technologies Inc. has awarded the Agilent Research Catalyst Award to the Eastern Institute of Technology in Ningbo. This award, presented to Professor Zongwei Cai, acknowledges his significant contributions to developing advanced methods for detecting per- and polyfluoroalkyl substances (PFAS) and other emerging contaminants, highlighting their relevance to environmental and public health.
Read more →AAgilent to Announce Third-Quarter Fiscal Year 2026 Financial Results on Aug. 26
Agilent Technologies Inc. will announce its financial results for Q3 FY 2026 on August 26. The announcement will occur after market close, followed by a conference call at 1:30 p.m. PDT to discuss the results. Investors can access the call via a webcast, with a recording available for 90 days.
Read more →AAgilent Receives EU Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Agilent Technologies has announced the receipt of EU certification for its PD-L1 IHC 22C3 pharmDx. This companion diagnostic is designed to help identify patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1. Eligible patients may benefit from treatment with Merck's KEYTRUDA, an anti-PD-1 therapy.
Read more →AAgilent Receives FDA Approval for PD-L1 IHC 28-8 pharmDx in Esophageal Squamous Cell Carcinoma (ESCC), Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinoma
Agilent Technologies has received FDA approval for its PD-L1 IHC 28-8 pharmDx assay. This companion diagnostic is designed to identify patients with esophageal squamous cell carcinoma, gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma who may benefit from OPDIVO treatment. This approval marks a significant advancement in personalized cancer therapy.
Read more →AAgilent Expands Altura Portfolio with Inert Size Exclusion and PLRP-S Columns for Biotherapeutic Analysis
Agilent Technologies has expanded its Altura HPLC column portfolio with the introduction of new size exclusion chromatography (SEC) and PLRP-S columns. These columns are designed to enhance critical analytical workflows in biopharmaceutical development and production. They support various biotherapeutic modalities, including peptides, proteins, and oligonucleotides.
Read more →AAgilent Launches AI-Driven Analysis Module for Agilent xCELLigence RTCA eSight
Agilent has introduced a new AI-driven analysis module for its xCELLigence RTCA eSight platform. This enhancement aims to improve data analysis capabilities, although specific details about its functionalities and benefits are not provided in the article. The launch reflects Agilent's commitment to integrating advanced technologies into their products.
Read more →AAgilent Completes Acquisition of Biocare Medical
Agilent has successfully completed the acquisition of Biocare Medical. This strategic move is expected to enhance Agilent's capabilities in the medical diagnostics field. Further details regarding the implications of this acquisition have not been disclosed.
Read more →AAgilent Receives FDA Approval for Expanded Use of PD-L1 IHC 22C3 pharmDx on Dako Omnis in Esophageal Squamous Cell Carcinoma, Triple-Negative Breast Cancer, Cervical Cancer, and Gastric or Gastroesophageal Junction Adenocarcinoma
Agilent has received FDA approval for the expanded use of its PD-L1 IHC 22C3 pharmDx test on the Dako Omnis platform. This approval covers esophageal squamous cell carcinoma, triple-negative breast cancer, cervical cancer, and gastric or gastroesophageal junction adenocarcinoma. The expanded use of this diagnostic tool is expected to enhance treatment options for patients with these cancers.
Read more →A▲ +16.9%on this newsshared move
Agilent Introduces OpenLab Sync to Support Guided, Digital Execution in the Laboratory
Agilent has launched OpenLab Sync, a new platform designed to enhance digital execution in laboratories. This tool aims to support guided workflows and improve laboratory efficiency. The introduction of OpenLab Sync reflects Agilent's commitment to innovation in laboratory technology.
Read more →About Agilent Technologies, Inc.
Headquarters5301 STEVENS CREEK BLVD, SANTA CLARA, CA, 95051
Founded1999
BIOPHARMAWATCH ELITE PLUS
Trade the next A catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime